# Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

PMC · DOI: 10.3389/fphar.2024.1365927 · Frontiers in Pharmacology · 2024-01-15

## Full-text entities

- **Diseases:** Chronic kidney disease (MESH:D051436), bleeding (MESH:D006470), CKD (MESH:D012080), Congestive heart failure (MESH:D006333), hypofibrinogenemia (MESH:D000347), COPD (MESH:D029424), Skin and soft tissue infections (MESH:D018461)
- **Chemicals:** carbapenems (MESH:D015780), N-methylthio-tetrazole (MESH:C038625), cefoperazone/sulbactam (-), beta-lactam (MESH:D047090), tigecycline (MESH:D000078304)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10822909/full.md

---
Source: https://tomesphere.com/paper/PMC10822909